Jim Cramer Highlights Teva Pharmaceutical’s Growth Under CEO Richard Francis

Company Overview - Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the world's largest generic drug makers, producing medical products including generic pills, inhalers, and treatments for conditions like migraines and cancer [2]. Stock Performance - The stock of Teva has experienced a significant turnaround, gaining nearly 400% from its 2022 lows following a leadership change with Richard Francis taking over at the beginning of 2023 [1]. - Over the past 12 months, Teva's stock has increased by 54% [1]. - Despite a quarterly report that exceeded expectations, the company's full-year forecast was perceived as slightly light, leading to an initial stock drop of 9% after the announcement [1]. - The stock stabilized after the conference call and finished the day up more than 2% [1].